

Carolyn A Felix

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4471639/carolyn-a-felix-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

30
papers

1,566
citations

13
h-index

31
g-index

31
ext. papers

1,719
ext. citations

4.6
avg, IF

3.83
L-index

#	Paper	IF	Citations
30	KMT2A-MAML2 rearrangement emerged and regressed during neuroblastoma therapy without leukemia after 12.8-year follow-up. <i>Pediatric Blood and Cancer</i> , 2022 , 69, e29344	3	0
29	Expanding the genotypic and phenotypic spectrum in a diverse cohort of 104 individuals with Wiedemann-Steiner syndrome. <i>American Journal of Medical Genetics, Part A</i> , 2021 , 185, 1649-1665	2.5	0
28	Single-cell multiomics reveals increased plasticity, resistant populations and stem-cell-like blasts in KMT2A-rearranged leukemia. <i>Blood</i> , 2021 ,	2.2	4
27	Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia. <i>Oncogene</i> , 2019 , 38, 2241-2262	19	0
26	Genome-wide TOP2A DNA cleavage is biased toward translocated and highly transcribed loci. <i>Genome Research</i> , 2017 , 27, 1238-1249	9.7	36
25	Unique Familial MLL(KMT2A)-Rearranged Precursor B-Cell Infant Acute Lymphoblastic Leukemia in Non-twin Siblings. <i>Pediatric Blood and Cancer</i> , 2016 , 63, 1175-80	3	5
24	Predicting Clinical Dose-Exposure and Exposure-Response Relationships of Pan-Antiapoptotic BCL-2 Family Inhibitor Obatoclax in MLL Rearranged Infant Leukemias From Preclinical Disease Models and Adult Experience. <i>Blood</i> , 2011 , 118, 2580-2580	2.2	2
23	Infant leukemia 2010: a call to action for the west and the "four Asian Tigers". <i>Pediatric Blood and Cancer</i> , 2010 , 55, 1247-9	3	1
22	af9 Regulates gata2 Expression During Early Hemangioblast Specification and Vascular Pattern Formation In Zebrafish.. <i>Blood</i> , 2010 , 116, 2600-2600	2.2	0
21	A safer regimen for high-risk neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2009 , 53, 3-6	3	5
20	Specific MLL Partner Genes in Infant Acute Lymphoblastic Leukemia (ALL) Associated with Outcome Are Linked to Age and White Blood Cell Count (WBC) at Diagnosis: A Report On the Children's Oncology Group (COG) P9407 Trial.. <i>Blood</i> , 2009 , 114, 907-907	2.2	3
19	Zebrafish Mll Depletion Model Phenocopies Mammalian Mll Depletion and Implicates MLL as Master Regulator of Novel Developmental Hematopoietic Targets.. <i>Blood</i> , 2009 , 114, 3655-3655	2.2	0
18	Prospective tracing of MLL-FRYL clone with low MEIS1 expression from emergence during neuroblastoma treatment to diagnosis of myelodysplastic syndrome. <i>Blood</i> , 2008 , 111, 3802-12	2.2	14
17	Cloning and Characterization of the Zebrafish mll Ortholog.. <i>Blood</i> , 2007 , 110, 1249-1249	2.2	0
16	Topoisomerase II and the etiology of chromosomal translocations. <i>DNA Repair</i> , 2006 , 5, 1093-108	4.3	116
15	DNA Topoisomerase II Poisons and the Etiology of Acute Leukemia in Infants.. <i>Blood</i> , 2005 , 106, 2850-2850	0	1
14	Philadelphia Chromosome (Ph) ⁻ Negative, MLL-Rearranged AML Arising in a Patient Treated with Imatinib for CML.. <i>Blood</i> , 2005 , 106, 4880-4880	2.2	0

13	Cryptic MLL, AF10, ARMC3 Rearrangement in Secondary AML Creates ARMC3-MLL Fusion That Disrupts Gene Encoding Armadillo Repeats Similar to Major Cancer Genes.. <i>Blood</i> , 2005 , 106, 4345-4345	2.2	1
12	Bone Marrow Replacement with a Clone Harboring Novel t(4;11)(p12;q23) Involving MLL during Neuroblastoma Treatment Is Not Associated with Leukemia.. <i>Blood</i> , 2004 , 104, 2903-2903	2.2	2
11	NUP98 Translocation Breakpoints in Treatment-Related MDS Are Drug-Stimulated DNA Topoisomerase II Cleavage Sites.. <i>Blood</i> , 2004 , 104, 1970-1970	2.2	
10	Simultaneous determination of etoposide and its catechol metabolite in the plasma of pediatric patients by liquid chromatography/tandem mass spectrometry. <i>Journal of Mass Spectrometry</i> , 2001 , 36, 771-81	2.2	32
9	Leukemias related to treatment with DNA topoisomerase II inhibitors. <i>Medical and Pediatric Oncology</i> , 2001 , 36, 525-35		170
8	Potential role for DNA topoisomerase II poisons in the generation of t(11;20)(p15;q11) translocations. <i>Genes Chromosomes and Cancer</i> , 2000 , 29, 96-105	5	50
7	Leukemia in Infants. <i>Oncologist</i> , 1999 , 4, 225-240	5.7	67
6	Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. <i>Nature Genetics</i> , 1999 , 23, 166-75	36.3	897
5	Potential role for wild-type p53 in leukemias with MLL gene translocations. <i>Oncogene</i> , 1998 , 16, 1351-6	9.2	23
4	RAS mutations in pediatric leukemias with MLL gene rearrangements 1998 , 21, 270-275		27
3	Panhandle Polymerase Chain Reaction Amplifies MLL Genomic Translocation Breakpoint Involving Unknown Partner Gene. <i>Blood</i> , 1997 , 90, 4679-4686	2.2	30
2	p53 gene mutations in pediatric brain tumors. <i>Medical and Pediatric Oncology</i> , 1995 , 25, 431-6		60
1	Therapy-related leukemias774-804		1